J 2021

Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study

KAYSER, S., R. K. HILLS, R. LANGOVA, M. KRAMER, F. GUIJARRO et. al.

Základní údaje

Originální název

Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study

Autoři

KAYSER, S. (garant), R. K. HILLS, R. LANGOVA, M. KRAMER, F. GUIJARRO, Zuzana ŠUSTKOVÁ (203 Česká republika, domácí), E. H. ESTEY, C. M. SHAW, Zdeněk RÁČIL (203 Česká republika, domácí), Jiří MAYER (203 Česká republika, domácí), Pavel ZAK (203 Česká republika), M. R. BAER, A. M. BRUNNER, T. SZOTKOWSKI, Petr CETKOVSKY (203 Česká republika), D. GRIMWADE, R. B. WALTER, A. K. BURNETT, A. D. HO, G. EHNINGER, C. MULLER-TIDOW, U. PLATZBECKER, C. THIEDE, C. ROLLIG, A. SCHULZ, G. WARSOW, B. BRORS, J. ESTEVE, N. H. RUSSELL, R. F. SCHLENK a M. J. LEVIS

Vydání

British journal of haematology, England, Wiley-Blackwell, 2021, 0007-1048

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 8.615

Kód RIV

RIV/00216224:14110/21:00120102

Organizační jednotka

Lékařská fakulta

UT WoS

000613871100001

Klíčová slova anglicky

acute myeloid leukaemia; t(8;16)(p11;p13)/MYST3-CREBBP; whole-genome sequencing; allogeneic haematopoietic cell transplantation; outcome

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 7. 6. 2021 08:50, Mgr. Tereza Miškechová

Anotace

V originále

In acute myeloid leukaemia (AML) t(8;16)(p11;p13)/MYST3-CREBBP is a very rare abnormality. Previous small series suggested poor outcome. We report on 59 patients with t(8;16) within an international, collaborative study. Median age was 52 (range: 16-75) years. AML was de novo in 58%, therapy-related (t-AML) in 37% and secondary after myelodysplastic syndrome (s-AML) in 5%. Cytogenetics revealed a complex karyotype in 43%. Besides MYST3-CREBBP, whole-genome sequencing on a subset of 10 patients revealed recurrent mutations in ASXL1, BRD3, FLT3, MLH1, POLG, TP53, SAMD4B (n = 3, each), EYS, KRTAP9-1 SPTBN5 (n = 4, each), RUNX1 and TET2 (n = 2, each). Complete remission after intensive chemotherapy was achieved in 84%. Median follow-up was 5 center dot 48 years; five-year survival rate was 17%. Patients with s-/t-AML (P = 0 center dot 01) and those with complex karyotype (P = 0 center dot 04) had an inferior prognosis. Allogeneic haematopoietic cell transplantation (allo-HCT) was performed in 21 (36%) patients, including 15 in first complete remission (CR1). Allo-HCT in CR1 significantly improved survival (P = 0 center dot 04); multivariable analysis revealed that allo-HCT in CR1 was effective in de novo AML but not in patients with s-AML/t-AML and less in patients exhibiting a complex karyotype. In summary, outcomes of patients with t(8;16) are dismal with chemotherapy, and may be substantially improved with allo-HCT performed in CR1.

Návaznosti

NV15-25809A, projekt VaV
Název: Národní program studia mutací a klonality leukemických buněk u pacientů s akutní myeloidní leukémií